May 1, 1988European Heart Journal
Multiple comparison of several antiarrhythmic agents by acute oral drug testing in patients with chronic ventricular arrhythmias
Key result
Flecainide and propafenone outperform other acute oral antiarrhythmics with up to ~69% ventricular arrhythmia suppression.
- n=40
Why the study?
Does acute oral drug testing effectively identify the optimal antiarrhythmic agent for patients with chronic ventricular arrhythmias?
Population
40 patients with chronic ventricular arrhythmias
Comparison
Single oral dose of antiarrhythmic drugs… vs Intra-patient comparison across different…
Design
Cohort
Follow-up
72 hours
Authors
Discussion
Loading...
Member takes
Implication
May support acute oral testing to tailor antiarrhythmic selection in ventricular arrhythmias; hypothesis-generating pending randomized outcome trials.
Structured PICO
Does acute oral drug testing effectively identify the optimal antiarrhythmic agent for patients with chronic ventricular arrhythmias?
P
Population
40 patients with chronic ventricular arrhythmias who received single oral doses of seven different antiarrhythmic drugs to evaluate acute efficacy.
I
Intervention
Single oral dose of antiarrhythmic drugs (flecainide 200 mg, propafenone 450 mg, disopyramide 300 mg, mexiletine 400 mg, tocainide 800 mg, verapamil 160 mg, propranolol 120 mg) followed by full dosage of the most effective drug for 72 hours
C
Comparator
Intra-patient comparison across different antiarrhythmic drugs
O
Outcome
Suppression of complex ventricular arrhythmias and a greater than 90% reduction in premature ventricular beats lasting for at least 2 hsurrogate
Acute oral drug testing is a feasible and practical approach to rapidly select the most effective antiarrhythmic drug for individual patients with chronic ventricular arrhythmias.
Cite This Study
Facchini et al. (1988) studied chronic ventricular arrhythmias (n=40). Multiple antiarrhythmic agents was evaluated on Suppression of complex ventricular arrhythmias and >90% reduction in premature ventricular beats lasting for at least 2 h. Acute oral drug testing demonstrated varying efficacy among antiarrhythmic agents, with flecainide (69.4%) and propafenone (67.5%) achieving the highest rates of arrhythmia suppression.